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Abstract
With increasing cancer diagnoses and an increase of chemotherapy treatment, many patients
complain of cognitive decline during the duration of treatment as well as once treatment has been
completed. The purpose of this review is to compile relevant research regarding chemotherapyrelated cognitive impairment and its implications for the care of cancer patients. Peer-reviewed
articles and studies focusing on the impact of chemotherapy on cognitive function were
evaluated, resulting in a total of 12 studies utilized in this review. Overall, it has been found that
a large percentage of patients undergoing chemotherapy treatment report a subjective decline in
cognitive functioning, but there is little evidence of objective decline shown by cognitive testing
and fMRI data. While more research needs to be conducted to find whether there is measurable
objective decline in patients receiving chemotherapy treatment, understanding and managing the
symptoms should be a priority for healthcare providers delivering chemotherapy treatment.

Introduction
Chemotherapy is a commonly used treatment for a variety of cancers, and the longlasting effects of chemotherapy treatment have been widely documented. One of the highest
concerns is cognitive impairment during and after treatment and is commonly referred to as
“chemobrain” (Perrier et al., 2018). The effects of chemotherapy vary according to each patient,
however, in approximately 15-35% of cases cognitive dysfunction has been reported (Martin et
al., 2020). Chemotherapy treatment most commonly affects memory, learning, attention,
concentration, reasoning, processing speed, executive functions, and visuo-spatial skills
(Mounier et al., 2020). In turn, the adverse effects of chemotherapy can result in anxiety, stress,
depression, and fatigue, among other symptoms (Alhareeri et al., 2020). Due to the increasing
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life expectancy after cancer diagnosis, more effects of chemotherapy-related cognitive
impairment (CRCI) are being recognized and reported, most often in breast cancer patients
(Boscher et al., 2020).
The direct cause and etiology of chemotherapy-related cognitive impairment is still
unknown, yet the occurrence is thought to be multifactorial (Kessler et al., 2019; Martin et al.,
2020). Commonly reported causes include the direct neurotoxic effects, hormonal changes,
oxidative stress, dysregulation of the immune system, and vascular damage (Martin et al., 2020).
However, it has been found that cognitive impairment exists prior to the initiation of therapy in
some cases, indicating that the cancer itself could be a contributing factor to cognitive decline
(Mounier et al., 2020). Introduction of stress, anxiety, and depression related to cancer diagnosis
and subsequent treatment may also impair cognitive function in cancer patients (Martin et al.,
2020).
Due to the wide-reaching cognitive effects that chemotherapy can have on patients,
improving and maintaining quality of life is of the utmost importance (Boscher et al., 2020).
With an increased number of cancer survivors due to better detection and advances in cancer
treatment, the long-term effects of chemotherapy need to be mitigated and researched more
thoroughly (Fernandez et al., 2020). Providing care for patients with declining cognitive function
presents a myriad of challenges for their nurses, doctors, and family members (Cheng et al.,
2019). Because of these factors, there are many nursing implications for the care of cancer
patients undergoing chemotherapy treatment and those in remission.
The purpose of this literature review is to investigate how chemotherapy treatment affects
cognitive function in cancer patients. This review is presented using the following themes:
potential causes of this cognitive decline, effects of chemotherapy treatment, and subjective
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patient reports. The Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog)
questionnaire has become widely used among providers, yet its use and scoring has not been
standardized (Costa et al., 2018). Utilizing these topics, the question of whether chemotherapy
affects cognitive function will be explored.
While there has been extensive research conducted on this topic, there are many gaps
present within the literature. For instance, while the causes of cognitive dysfunction related to
chemotherapy treatment are noted to be multifactorial, there has been little research conducted
on the potential specific causes (Martin et al., 2020). In addition, many patients report subjective
cognitive decline, but limited studies have carried out research on objective cognitive
impairment as evidenced by alterations within the brain, and the studies that have focused on this
area have not had compelling results (Cheng et al., 2019). Even with the use of FACT-Cog,
compiling the incidence of CRCI among cancer patients has been inconsistent and the utilization
of this assessment tool varies with each provider (Costa et al., 2018). Many of the studies
presented in this review did not have statistically significant conclusions, which also indicate the
need for further investigation on how chemotherapy affects cognitive function. While advances
have been made in monitoring and treating this cognitive impairment, more needs to be done.

Methods
A thorough review of literature and data extraction was completed using MEDLINE
Complete, CINAHL, and PubMed. A distinguished professor and health sciences librarian at the
University of Arkansas provided expertise and support with finding applicable research articles
that met the inclusion criteria. The key words used in all searches were: chemotherapy, cancer,
cognitive, cognitive impairment or dysfunction. The inclusion criteria for the databases searched
were articles that contained the keywords, written in English, and peer-reviewed. Excluded from
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the review were articles published before 2015. Additionally the criteria focused solely on
chemotherapy treatments and outcomes. When using CINAHL, a total of 1,019 articles were
relevant. These were reviewed and evaluated to ensure the inclusion criteria was met. Of these
articles, three studies were found and were utilized in this review that focused on the use of
magnetic resonance imaging in visualizing structural changes within the brain before, during and
after chemotherapy. Searching PubMed produced a total of 1,806 results. After incorporating the
inclusion and exclusion criteria, one article was used from this search. The study used the
Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) version 3 in the assessment of
cognitive function in patients undergoing chemotherapy treatment for cancer, which was
analyzed for this review. MEDLINE Complete was used to search for additional articles. The
keys words for the search were chemotherapy and cancer and cognitive.
This search yielded 2,061 articles. Of these articles, 39 were found that included the use of
keywords and were applicable to the literature review. However, three were found that did not
meet the publishing date of 2015, one was focused on the use of other cancer treatment rather
than chemotherapy, and one had not yet been fully published and was unavailable to the public.
In total, 35 articles were found that met the inclusion criteria. Once the literature was extensively
review and examined, a total of 12 articles were chosen to be included and are the focus of this
review.
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Figure 1

Results
Causes of Cognitive Decline
As discussed previously, the causes of CRCI remain mostly unknown, however the
incidence is likely to be multifactorial. Martin et al. (2020) proposes five different causes: the
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direct neurotoxic effects of chemotherapy, induced hormonal changes, oxidative stress, immune
system dysregulation, and vascular damage. Underlying stress, anxiety, and depression may also
play a role in advancing CRCI in many patients (Martin et al., 2020).
Some chemotherapeutic agents have been shown to cross the blood brain barrier (BBB)
and can cause direct neurotoxic injury on the central nervous system (CNS) (Mounier et al.,
2020). However, Hernandez et al. (2020) argues that most chemotherapeutic treatments do not
readily cross the BBB, rather that the integrity of the BBB is harmed when peripheral molecules
enter and cause injury of the CNS, not those directly associated with chemotherapy treatment.
Chemotherapy can also impact hormone secretion and lead to cognitive problems (Martin et al.,
2020). For example, estrogen and testosterone, which are neuroprotective hormones, are known
to be affected by chemotherapy (Martin et al., 2020). With the decrease of these hormones, the
process of cognitive decline can be accelerated (Mounier et al., 2020). Adding to the
neurotoxicity effects, many chemotherapeutic agents induce oxidative stress both directly and
indirectly (Hernandez et al., 2020). This is caused by an “imbalance between reactive oxygen
species (ROS) production, including free radicals and peroxides, and the biological systems
oxidant defense mechanisms” (Mounier et al., 2020). The byproducts of oxidative stress related
to chemotherapy treatment can potentially cause damage to the CNS blood vessels which can
impact perfusion to other blood vessels within the CNS, causing CRCI effects (Mounier et al.,
2020). Inflammation due to the release of immune system mediators may be involved in
promoting or exacerbating CRCI (Hernandez et al., 2020). Processing speed, executive function,
spatial ability, and reaction time are all impacted by inflammatory cytokine release which crosses
the BBB and causes cognitive impairment (Martin et al., 2020). The release of these mediators
can cause neuroinflammation which negatively impacts neurogenesis and disrupts the
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myelination process, all impacting cognitive function (Mounier et al., 2020). Chemotherapy has
the ability to damage blood vessels which can impact blood flow to blood vessels within the
brain, henceforth causing a decline in cognition (Martin et al., 2020). This can cause a disruption
of cerebral blood flow and blood vessel density, notably in the hippocampus which plays a large
role in memory and learning (Mounier et al., 2020).
Effects of Treatment
Perrier et al. (2018) discovered with the use of fMRI that there was no statistical
significance between healthy controls and those undergoing treatment for breast cancer related to
changes in brain structure. However, the fMRIs did depict gray matter reduction in some areas of
the brain, while in other areas of the brain, gray matter volume increased one year after
chemotherapy treatment had stopped (Perrier et al., 2018). This indicates that a compensatory
mechanism may be occurring in patients undergoing chemotherapy treatment, where the brain
begins to adapt to the structural changes that the chemotherapy causes and therefore counteracts
by increasing the volume of gray matter in other areas of the brain (Perrier et al., 2018). The
fMRIs that were taken one month after cessation of therapy showed significant atrophy within
the brain which recovered one year after therapy had completed, as shown by follow-up fMRI
(Perrier et al., 2018). This supports the hypothesis that CRCI improves once the chemotherapy
course has been completed.
Chen et al. (2019) discovered that there was a significant increase in resting state brain
activity in some parts of the brain and a decrease in others from before the initiation of
chemotherapy to one month after chemotherapy was completed. However, there were no
differences between the controls and chemotherapy group in rs-fMRI results, which is an
indicator of intrinsic brain activity associated with cognitive function (Chen et al., 2019).
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Moreover, there was no significant difference in neuropsychological testing among groups,
which shows that there was not a large gap present that signified cognitive decline in the
domains of executive functioning, memory, language, processing speed, and attention (Chen et
al., 2019). Again, these results indicate a compensatory mechanism by the brain to counteract the
effects of chemotherapy, however in this study there was no statistically significant data present
that indicated a decline in cognition in chemotherapy patients (Chen et al., 2019).
Kessler et al. (2020) organized the patients into three different biotype groups, according
to the most similar connectome features within their brain, which were found using fMRI. It was
found that biotype 1 performed lower compared to the control group in all cognitive tests,
biotype 3 did poorer on 4 out of 5 cognitive tests, and biotype 2 had a low performance on letter
fluency only (Kessler et al., 2019). Furthermore, the subjects completed the Clinical Assessment
of Depression (CAD) and the Behavioral Rating Inventory of Executive Function (BRIEF-A) to
report subjective cognitive impairment (Kessler et al., 2019). Results from these questionnaires
showed that biotype 1 had lower perceived cognitive function and lower psychological
functioning, whereas biotype 2 only showed lower executive functioning, and biotype 3 had no
significant difference compared to controls (Kessler et al., 2019). These results show that brain
structure plays a large role in determining how chemotherapy will affect cognitive functioning in
cancer patients (Kessler et al., 2019).
In assessing functional connection within the brain, it was found that breast cancer
survivors who had received chemotherapy treatment and complained of cognitive impairment
showed weaker functional connectivity within the frontoparietal system of the brain compared to
breast cancer survivors who did not complain of cognitive decline (Piccirillo et al., 2015). The
results from this were found using rs-fcMRI data and cognitive impairment was measured using
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the Global Rating of Cognition (GRC) (Piccirillo et al., 2015). Those who had the highest GRC
scores, indicating cognitive impairment, had the lowest functional connection strength (Piccirillo
et al., 2015). These results outline that while not every cancer patient will have cognitive
impairment, those that do exhibit changes within the structure of their brain that may be the
cause of declining cognition (Piccirillo et al., 2015).
Telomere lengths were also assessed to discover the impact of chemotherapy on
cognition (Alhareeri et al., 2020). Using fluorescence in situ hybridization (FISH), chromosomespecific telomere values were analyzed in order to find whether chemotherapy caused telomere
length changes and if those changes resulted in cognitive effects (Alhareeri et al., 2020).
Throughout the duration of chemotherapy, telomere lengths were measured and 84.8% showed a
decrease in length (Alhareeri et al., 2020). It was found that there is a significant association of
seven cognitive domains with chromosome-specific telomere values (Alhareeri et al., 2020). In
addition, a significant relationship was found between visual memory domain and numerous
individual telomeres on specific chromosomes (Alhareeri et al., 2020). Therefore it can be
hypothesized that the shortening of telomere length caused by chemotherapy can negatively
impact cognitive function (Alhareeri et al., 2020).
Patient Reports
Janelsins et al. (2017) implemented the use of FACT-Cog to determine perceived
cognitive decline in breast cancer patients treated with chemotherapy. From prechemotherapy to
post-chemotherapy, 45.2% of breast cancer patients reported meaningful cognitive decline
compared to the healthy controls (Janelsins et al., 2017). However, FACT-Cog scores improved
within six months of cessation of chemotherapy (Janelsins et al., 2017). This indicates that while
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the incidence of perceived cognitive function is high, there is evidence of improvement once
chemotherapy has ended (Janelsins et al., 2017).
Boscher et al. (2020) found that a variety of factors impacted patient’s FACT-Cog scores,
including age, employment, trouble sleeping, medical treatment for mental health, chemotherapy
treatment, anxiety, depression, fatigue, and PTSD. It was shown that those who received
chemotherapy were more likely to report and suffer from cognitive decline (Boscher et al.,
2020). However, the cause of this cognitive dysfunction was proven to be multifactorial because
it was shown that the patients’ employment status, diagnoses of mental health issues, as well as
sleep difficulties also contributed to subjective cognitive complaints (Boscher et al., 2020).
Therefore, it is likely that the cause of cognitive impairment in patients undergoing
chemotherapy treatment is due to a variety of external factors, rather than solely the
administration of chemotherapy for cancer (Boscher et al., 2020).
The Blessed Orientation Memory Concentration Test was also used to assess perceived
cognitive function in older adults with breast cancer (Nakamura et al., 2020). Through the use of
this test along with subjective reports of patients, 27% suffered from cognitive impairment
(Nakamura et al., 2020). However, those that reported this decline were older in age, had less
education, and not employed full-time (Nakamura et al., 2020). This corresponds with the
hypothesis that cognitive impairment is impacted by other factors rather than solely the
administration of chemotherapy (Nakamura et al., 2020).

See Table 1 for an outline of the studies that were reviewed. Most of the studies utilized
were longitudinal, therefore the strength of evidence is less than that of randomized controlled
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trials. This is because the patient population that is being studied is unable to participate in
randomized controlled trials due to their diagnosis of cancer and the need to undergo
chemotherapy treatment.

Table 1
Alhareeri, A. A., Archer,
K. J., Fu, H., Lyon, D.
E., Elswick, R. K., Jr.,
Kelly, D. L.,
Starkweather, A. R.,
Elmore, L. W., Bokhari,
Y. A., & Jackson-Cook,
C. K.
Chen, B. T., Jin, T.,
Patel, S. K., Ye, N., Ma,
H., Wong, C. W.,
Rockne, R. C., Root, J.
C., Saykin, A. J., Ahles,
T. A., Holodny, A. I.,
Prakash, N., Mortimer,
J., Waisman, J., Yuan,
Y., Li, D., Sedrak, M. S.,
Vazquez, J., Katheria, V.,
& Dale, W
Boscher, C., Joly, F.,
Benedicte, C., Humbert,
X., Grellard, J., Binarelli,
G., Tron, L., Licaj, I.,
Lange, M.

2020

United States

Longitudinal cohort
study

Certain chemotherapy agents
shortened telomere lengths which
caused lower cognitive scores.

Level 4
Evidence

2019

United States

Longitudinal cohort
study

Chemotherapy may impact
intrinsic brain activity in breast
cancer patients, negatively
affecting their cognitive function.

Level 4
Evidence

2020

France

Qualitative Study

Level 6
Evidence

Costa, D., Loh, V.,
Birney, D. P., Dhillon, H.
M., Fardell, J. E.,
Gessler, D., Vardy, J. L.

2018

Australia

Qualitative Study

Fernandez, H. R., Varma,
A., Flowers, S. A., &
Rebeck, G. W.

2020

United States

Case-Control Study

Janelsins, M. C.,
Heckler, C. E., Peppone,
L. J., Kamen, C.,
Mustian, K. M., Mohile,

2017

United States

Longitudinal Study

About half of breast cancer
patients undergoing
chemotherapy reported cognitive
complaints, which could be
impacted by age, employment
status, or mental health issues.
The Functional Assessment of
Cancer Therapy-Cognitive
(FACT-Cog) can be used to
assess the perceived cognitive
function in cancer patients and its
use should be standardized in
order to assess the cognitive
domains of those undergoing
chemotherapy
The APOE gene related to the
development of Alzheimer’s
disease could make those who
carry this gene more susceptible
to developing CRCI while
undergoing chemotherapy
treatment for cancer
Patients receiving chemotherapy
treatment for breast cancer
reported a significant increase in
cognitive impairment from

Level 6
evidence

Level 4
Evidence

Level 4
Evidence
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S. G., Magnuson, A.,
Kleckner, I. R., Guido, J.
J., Young, K. L., Conlin,
A. K., Weiselberg, L. R.,
Mitchell, J. W.,
Ambronsone, C. A.,
Ahles, T. A., Morrow, G.
R
Kesler, S. R., Petersen,
M. L., Rao, V., Harrison,
R. A., Palesh, O.
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prechemotherapy to
postchemotherapy. This was also
likely impacted by anxiety,
depression, and decreased
cognitive reserve.

2020

United States

Longitudinal Study

Martin, B. R., Fernandez
Rodriguez, E. J., Rihuete
Galve, M. I., Cruz
Hernandez, J. J.

2020

Spain

Longitudinal Study

Mounier, N. M., AbdelMaged, A. E.-S.,
Wahdan, S. A., Gad, A.
M., & Azab, S. S.

2020

Egypt

Systematic Review

Nakamura, Z. M., Deal,
A. M., Nyrop, K. A.,
Damone, E. M., Muss, H.
B

2020

United States

Qualitative Study

Perrier, J., Viard, A.,
Levy, C., Morel, N.,
Allouache, D., Noal, S.,
Joly, F., Eustache, F., &
Giffard, B.

2020

France

Longitudinal Study

Piccirillo, J. F., Hardin,
F. M., Nicklaus, J.,
Kallogjeri, D., Wilson,
M., Ma, C. X., Coalson,
R. S., Shimony, J.,
Schlaggar, B. L.

2015

United States

Case-Control Study

Using fMRI data, different
biotypes among breast cancer
patients were identified and
studied which show that certain
genetic markers make some
patients more susceptible to
CRCI.
Cognitive performance declined
in patients diagnosed with breast
cancer and receiving
chemotherapy and did not
completely recover two months
after the cessation of treatment.
Those who had anxiety or
depression had worse cognitive
performance.
Explored the underlying causes
of CRCI including neurotoxicity,
blood brain barrier disruption,
oxidative stress, vascular
damage, and immune system
dysregulation.
27% of those receiving
chemotherapy reported cognitive
impairment. This was associated
with an increase of age, less
education, and not being
employed full-time
Breast cancer patients
undergoing chemotherapy had
gray matter atrophy in some
areas of the brain with an
increase in gray matter volumes
in other areas. The atrophy either
persisted or recovered after one
year of treatment, depending on
the location of the atrophy.
Using fMRI, it was found that
those who reported cognitive
impairment after chemotherapy
treatment had disrupted restingstate functional connectivity
within the brain which may
impact attention and executive
functioning.

Level 4
Evidence

Level 4
Evidence

Level 5
Evidence

Level 6
Evidence

Level 4
Evidence

Level 4
Evidence
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Discussion
In analyzing these studies, it is evident that more research over CRCI needs to be
completed. While it has been widely thought that chemotherapy is a direct cause of cognitive
impairment, research has found that many factors may play a role in CRCI and that the type of
cancer and chemotherapy treatment may determine the extent of symptoms, along with genetic
predispositions (Fernandez et al., 2020). The results of many of these studies differed: while
some reported statistically significant objective cognitive decline, others did not, but many
subjects reported subjective cognitive impairment. A major finding in many of the studies
presents that while patients may perform within normative ranges on cognitive tests, they
subjectively report cognitive decline that is relevant to that patient, even though it cannot be
objectively analyzed (Piccirillo et al., 2015). Martin et al. (2020) found that “all cognitive
domains studied were affected during chemotherapy, although not all shared the same
impairment” and this was found through the use of subjective questionnaires that were
completed by the subjects. On the other hand, the shortening of telomere lengths was visualized
after chemotherapy treatment, which may be related to cognitive impairment among cancer
patients (Alhareeri et al., 2020). As is evident, the occurrence of CRCI varies among patient
population and is more often subjectively reported, rather than objectively measured.
Due to the various types of studies that were reviewed, there is an inconsistency of
results. Nakamura et al. (2020) had a small sample size and was limited to a more active and
educated cohort that did not suffer from other variables that could impact cognitive impairment,
such as depression, anxiety, and stress. Due to the lack of variability among patients in this
study, a comprehensive view on how chemotherapy affects cognitive function was not achieved
(Nakamura et al., 2020).
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The FACT-Cog scoring tool implementation has not yet been standardized and may lead
to discrepancies among cognitive function in cancer patients (Costa et al., 2018). Along with
this, FACT-Cog scores have a statistically insignificant relationship with objective cognitive
function analysis, such as testing and fMRI data, meaning that more research needs to be done as
to the efficacy of this tool in measuring cognitive function in cancer patients (Costa et al., 2018).
In one of the studies utilizing fMRI to analyze brain changes throughout the course of
chemotherapy, limitations were present which included a short follow-up duration, small sample
size, different stages of cancer, and different chemotherapy treatment which could have
contributed to the insignificant relationship between the neuropsychological testing and intrinsic
brain activity associated cognitive function (Chen et al., 2019). All of these studies reviewed and
presented had limitations that could have impacted the results.

Conclusion
Regardless of whether objective cognitive decline exists in cancer patients undergoing
chemotherapy, there continue to be subjective reports of cognitive decline that need to be
addressed. Even though the evidence is inconclusive supporting changes in brain structure due to
chemotherapy, the occurrence of CRCI and fear of “chemobrain” remain prevalent among cancer
patients. Because of this, guidelines for clinical practice are needed. For example, developing
interventions, both pharmacological and behavioral, should be a priority among providers who
give care to those undergoing chemotherapy treatment (Piccirillo et al., 2015). In addition, the
use and structure of FACT-Cog should be standardized across clinical practice so that subjective
cognitive complaints can be better monitored before, during, and after treatment (Costa et al.,
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2018). With the proper use of the FACT-Cog clinical questionnaire, the incidence of CRCI may
be better understood and managed within the clinical setting (Costa et al., 2018).
Moving forward, it is evident that more research needs to be done. Studies focusing on
both subjective cognitive complaints through the use of questionnaires, as well as objective
cognitive complaints through the use of fMRI should be completed. A better understanding may
be gained through comparing and contrasting both sides of cognitive impairment using the same
group of subjects. Furthermore, adequate timing and follow-up should be performed in all
studies, as that was a limitation in multiple studies.
After reviewing all of the articles presented, it is evident that the occurrence CRCI is
clinically relevant and warrants further investigation. While the specific causes of CRCI remain
unknown and may be difficult to identify, there are many implications for caring for patients
suffering from cognitive decline. More studies evaluating how chemotherapy affects cognitive
function need to be completed so that evidence-based interventions could be utilized for better
patient outcomes. Overall, those undergoing chemotherapy for cancer treatment may suffer from
cognitive impairment, and therefore more needs to be done to address this issue.
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